Heidenreich PA, Bozkurt B (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc2021.12.012

Article  PubMed  PubMed Central  Google Scholar 

McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

Article  PubMed  Google Scholar 

Ahn R, Prasad V (2018) Do limitations in the design of Paradigm-HF justify the slow real world uptake of sacubitril/valsartan (Entresto)? Cardiovasc Drugs Ther 32:633–635

Article  PubMed  Google Scholar 

Yandrapalli S, Aronow WS, Mondal P et al (2017) Limitations of sacubitril/valsartan in the management of heart failure. Am J Therap 24:e234–e239

Article  Google Scholar 

Bernardez-Pereira S, Alvares-Ramires FJ, Tavares de Melo RF et al (2018) Was the enalapril dose too low in the PARADIGM-HF trial? Cardiol Rev 26:196–200

Article  PubMed  Google Scholar 

Mandrola J (2021) PARADISE-MI makes me question the benefits of sacubitril/valsartan. Medscape. Available on: https://www.medscape.com/viewarticle/951239

Pfeffer MA, Claggett B, Lewis EF et al (2021) Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med 385:1845–1855

Article  CAS  PubMed  Google Scholar 

Mann DL, Givertz MM, Vadere JM et al (2022) Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol 7:17–25

Article  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Anand IS et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

(2015) Sacubitril/Valsartan (Entresto) for Heart Failure. JAMA. 314:722–723. https://doi.org/10.1001/jama.2015.9398

Clinical Resource (2016) ACE Inhibitor antihypertensive dose comparison. Pharmacist's letter/prescriber's letter, Resource #321151

Begic E, Mandzuka M, Begic Z et al (2017) Antihypertensive therapy dose calculator AFMBE Proceedings 62:660–665

Google Scholar 

Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384

Article  CAS  PubMed  PubMed Central  Google Scholar 

Velazquez EJ, Morrow DA, DeVore AD et al (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380:539–548

Article  CAS  PubMed  Google Scholar 

Piepoli MF, Hussain RI, Comin-Colet J et al (2021) OUTSTEP-HF: randomized controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail 23:127–135

Article  CAS  PubMed  Google Scholar 

Desai AS, Solomon SD, Shah AM et al (2019) Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 322:1077–1084

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bano S, Bai P, Kumar S et al (2021) Comparison of sacubitril/valsartan versus enalapril in the management of heart failure. Cureus 13:e16332

PubMed  PubMed Central  Google Scholar 

Tsutsui H, Momomura S, Saito Y et al (2021) Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction. Results from the PARALLEL-HF study. Circ J 85:584–594

Article  CAS  PubMed  Google Scholar 

Halle M, Schobel C, Winzer EB et al (2021) A randomized clinical trial on the short-term effects of 12 week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study. Eur J Heart Fail 23:2073–2082

Article  CAS  PubMed  Google Scholar 

Khandwalla RM, Grant D, Birkeland K et al (2021) The AWAKE-HF study: sacubitril/valsartan impact on daily physical activity and sleep in heart failure. Am J Cardiovasc Drugs 21:241–254

Article  CAS  PubMed  Google Scholar 

Ghafur S, Zahid A, Sarkar H et al (2020) Effect of angiotensin receptor-neprilysin inhibit versus valsartan on cardiac status in patients with chronic heart failure with reduced ejection fraction: a randomized clinical trial in Rangpur Medical College Hospital. Bangladesh Open J Intern Med 10:21–34

CAS  Google Scholar 

Zhao Y, Tian LG, Zhang LX et al (2022) The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction. Pulm Circ 12:1–8

Article  Google Scholar 

Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100:2312–2318

Article  CAS  PubMed  Google Scholar 

Shahzeb Khan M, Fonarow GC, Ahmed A et al (2017) Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure. A meta-analysis Circ Heart Fail 10:1–8

Google Scholar 

Konstam MA, Neaton JD, Dickstein K et al (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374:1840–1848

Article  CAS  PubMed  Google Scholar 

Yasky J, Verho M, Erasmus TP et al (1996) Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. Br J Clin Pract 50:302–310

Article  CAS  PubMed  Google Scholar 

McAuley D (2017) DRUG COMPARISONS -ACE INHIBITORS – MED EQUIVALENTS. Global RPH. https://globalrph.com/medcalcs/drug-comparisons-ace-inhibitors-medication-equivalents/. Accessed 7 October 2023

Zabludowski J, Rosenfeld J, Akbary MA, Rangoonwala B, Schinzel S (1988) A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension. Curr Med Res Opin 11:93–106

Article  CAS  PubMed  Google Scholar 

Ruddy MC, Morczek WJ (1993) Comparison of enalapril and ramipril in patients with essential hypertension. Pharmacotherapy 13:224–228

Article  CAS  PubMed  Google Scholar 

(2023) Heart failure. Centers for Disease Control and Prevention. https://www.cdc.gov/heartdisease/heart_failure.htm. Accessed 7 October 2023

Mukhopadhyay A, Adhikari S, Li X et al (2022) Association between copayment amount and filling of medications for angiotensin receptor neprilysin inhibitors in patients with heart failure. J Am Heart Assoc 11:e027662. https://doi.org/10.1161/JAHA.122.027662

Article  PubMed  PubMed Central  Google Scholar